文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[赖氨酸40(己二胺四乙酸-铟-111)氨基]艾塞那肽-4,一种非常有前景的靶向胰高血糖素样肽-1(GLP-1)受体的配体。

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

作者信息

Wild Damian, Béhé Martin, Wicki Andreas, Storch Daniel, Waser Beatrice, Gotthardt Martin, Keil Boris, Christofori Gerhard, Reubi Jean Claude, Mäcke Helmut R

机构信息

Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.

出版信息

J Nucl Med. 2006 Dec;47(12):2025-33.


DOI:
PMID:17138746
Abstract

UNLABELLED: High levels of glucagon-like peptide-1 (GLP-1) receptor expression in human insulinomas and gastrinomas provide an attractive target for imaging, therapy, and intraoperative tumor localization, using receptor-avid radioligands. The goal of this study was to establish a tumor model for GLP-1 receptor targeting and to use a newly designed exendin-4-DTPA (DTPA is diethylenetriaminepentaacetic acid) conjugate for GLP-1 receptor targeting. METHODS: Exendin-4 was modified C-terminally with Lys(40)-NH(2), whereby the lysine side chain was conjugated with Ahx-DTPA (Ahx is aminohexanoic acid). The GLP-1 receptor affinity (50% inhibitory concentration [IC(50)] value) of [Lys(40)(Ahx-DTPA)NH(2)]exendin-4 as well as the GLP-1 receptor density in tumors and different organs of Rip1Tag2 mice were determined. Rip1Tag2 mice are transgenic mice that develop insulinomas in a well-defined multistage tumorigenesis pathway. This animal model was used for biodistribution studies, pinhole SPECT/MRI, and SPECT/CT. Peptide stability, internalization, and efflux studies were performed in cultured beta-tumor cells established from tumors of Rip1Tag2 mice. RESULTS: The GLP-1 receptor affinity of [Lys(40)(Ahx-DTPA)NH(2)]exendin-4 was found to be 2.1 +/- 1.1 nmol/L (mean +/- SEM). Because the GLP-1 receptor density in tumors of Rip1Tag2 mice was very high, a remarkably high tumor uptake of 287 +/- 62 %IA/g (% injected activity per gram tissue) was found 4 h after injection. This resulted in excellent tumor visualization by pinhole SPECT/MRI and SPECT/CT. In accordance with in vitro data, [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 uptake in Rip1Tag2 mice was also found in nonneoplastic tissues such as pancreas and lung. However, lung and pancreas uptake was distinctly lower compared with that of tumors, resulting in a tumor-to-pancreas ratio of 13.6 and in a tumor-to-lung ratio of 4.4 at 4 h after injection. Furthermore, in vitro studies in cultured beta-tumor cells demonstrated a specific internalization of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4, whereas peptide stability studies indicated a high metabolic stability of the radiopeptide in beta-tumor cells and human blood serum. CONCLUSION: The high density of GLP-1 receptors in insulinomas as well as the high specific uptake of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 in the tumor of Rip1Tag2 mice indicate that targeting of GLP-1 receptors in insulinomas may become a useful imaging method to localize insulinomas in patients, either preoperatively or intraoperatively. In addition, Rip1Tag2 transgenic mice represent a suitable animal tumor model for GLP-1 receptor targeting.

摘要

未标记:人胰岛素瘤和胃泌素瘤中高水平的胰高血糖素样肽-1(GLP-1)受体表达为使用受体亲和放射性配体进行成像、治疗及术中肿瘤定位提供了一个有吸引力的靶点。本研究的目的是建立一个用于GLP-1受体靶向的肿瘤模型,并使用一种新设计的艾塞那肽-4-二乙三胺五乙酸(DTPA)偶联物进行GLP-1受体靶向。 方法:艾塞那肽-4在C末端用赖氨酸(40)-NH₂修饰,其中赖氨酸侧链与氨基己酸-DTPA(Ahx是氨基己酸)偶联。测定了[赖氨酸(40)(氨基己酸-DTPA)NH₂]艾塞那肽-4的GLP-1受体亲和力(50%抑制浓度[IC₅₀]值)以及Rip1Tag2小鼠肿瘤和不同器官中的GLP-1受体密度。Rip1Tag2小鼠是在明确的多阶段肿瘤发生途径中发生胰岛素瘤的转基因小鼠。该动物模型用于生物分布研究、针孔单光子发射计算机断层扫描/磁共振成像(SPECT/MRI)以及SPECT/计算机断层扫描(CT)。在从Rip1Tag2小鼠肿瘤建立的培养β肿瘤细胞中进行了肽稳定性、内化和外排研究。 结果:发现[赖氨酸(40)(氨基己酸-DTPA)NH₂]艾塞那肽-4的GLP-1受体亲和力为2.1±1.1 nmol/L(平均值±标准误)。由于Rip1Tag2小鼠肿瘤中的GLP-1受体密度非常高,注射后4小时发现肿瘤摄取率显著高,为287±62%IA/g(每克组织注射活性百分比)。这通过针孔SPECT/MRI和SPECT/CT实现了出色的肿瘤可视化。与体外数据一致,在Rip1Tag2小鼠中,[赖氨酸(40)(氨基己酸-(铟-111)DTPA)NH₂]艾塞那肽-4在胰腺和肺等非肿瘤组织中也有摄取。然而,与肿瘤相比,肺和胰腺的摄取明显较低,注射后4小时肿瘤与胰腺的比值为13.6,肿瘤与肺的比值为4.4。此外,在培养的β肿瘤细胞中的体外研究表明[赖氨酸(40)(氨基己酸-(铟-111)DTPA)NH₂]艾塞那肽-4有特异性内化,而肽稳定性研究表明放射性肽在β肿瘤细胞和人血清中具有高代谢稳定性。 结论:胰岛素瘤中GLP-1受体的高密度以及[赖氨酸(40)(氨基己酸-(铟-111)DTPA)NH₂]艾塞那肽-4在Rip1Tag2小鼠肿瘤中的高特异性摄取表明,靶向胰岛素瘤中的GLP-1受体可能成为一种有用的成像方法,用于在术前或术中定位患者的胰岛素瘤。此外,Rip1Tag2转基因小鼠代表了一种适用于GLP-1受体靶向的动物肿瘤模型。

相似文献

[1]
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

J Nucl Med. 2006-12

[2]
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Clin Cancer Res. 2007-6-15

[3]
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

J Nucl Med. 2010-7

[4]
Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.

J Nucl Med. 2015-10

[5]
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.

J Nucl Med. 2016-8

[6]
Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.

PLoS One. 2017-1-19

[7]
68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.

Eur J Nucl Med Mol Imaging. 2010-1-29

[8]
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

EJNMMI Res. 2014-2-16

[9]
Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

Lancet Diabetes Endocrinol. 2013-7-25

[10]
Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.

Eur J Nucl Med Mol Imaging. 2002-5

引用本文的文献

[1]
Molecular imaging of neuroendocrine tumors: Current applications and future trends.

Diagn Interv Imaging. 2025-5-21

[2]
Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes.

Molecules. 2025-2-21

[3]
Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities.

Front Mol Biosci. 2023-9-15

[4]
F-labeled PEGylated exendin-4 imaging noninvasively differentiates insulinoma from an accessory spleen: the first case report of [18F]FB(ePEG12)12-exendin-4 positron emission tomography/computed tomography for insulinoma.

Front Endocrinol (Lausanne). 2023

[5]
Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.

EJNMMI Radiopharm Chem. 2023-9-4

[6]
New Long-Acting [Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation.

J Med Chem. 2023-6-22

[7]
Exendin-4-Conjugated Manganese Magnetism-Engineered Iron Oxide Nanoparticles as a Potential Magnetic Resonance Imaging Contrast Agent for Tracking Transplanted β-Cells.

Nanomaterials (Basel). 2021-11-21

[8]
New Directions in Imaging Neuroendocrine Neoplasms.

Curr Oncol Rep. 2021-11-4

[9]
Distinctive detection of insulinoma using [F]FB(ePEG12)12-exendin-4 PET/CT.

Sci Rep. 2021-7-22

[10]
Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.

Ann Nucl Med. 2021-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索